• Onset: 2-4 weeks of consistent dosing before subjective effect emerges; some users report nothing at 8 weeks (placebo proportion high)
• Quality: More subtle than rhodiola, less stimulating. Described as "stress floor" — same demands, less depleting, no noticeable mood lift or focus sharpening
• At higher doses (≥600 mg standardized): Mild stimulation, occasionally jitteriness; some PM users report insomnia
• Cycle awareness: Effect can plateau or fade after 6-8 weeks of continuous use; classical Russian protocols cycled to maintain responsiveness
• Discontinuation: No withdrawal syndrome; effect fades over days to weeks without rebound
• Placebo proportion: High. Many users report nothing distinguishable from placebo over 6-week trials — this is consistent with the modern null-RCT pattern

Dylan-specific subjective prediction (LOW confidence): Likely nothing distinguishable from rhodiola if both are taken concurrently — same mechanism slot. If trying eleuthero solo (e.g., during a rhodiola washout), expect at most a mild "less drained at end of day" effect over 4-6 weeks, with high probability of "nothing noticeable." Not a compound to invest emotional weight in.

• Tolerance buildup: Minimal at standard doses; some functional tolerance reported after 6-8 weeks of continuous use (effect fades)
• Recommended cycle: 4-6 weeks on, 2 weeks off (Russian classical pattern) — empirical, designed to maintain responsiveness
• Reset protocol: 2-4 weeks off restores most users to baseline responsiveness
• No withdrawal syndrome. Effect fades; nothing else.
• No cross-tolerance with rhodiola or ashwagandha at the experiential level (despite mechanistic overlap on HPA — users often report different subjective profiles)

Synergistic with

• Rhodiola (in Dylan's V4): Both classical Russian adaptogens; rhodiola is more stimulating + monoamine-skewed, eleuthero more immune-skewed. However, stacking them simultaneously is mechanistically redundant. Better to alternate by 4-6 week blocks. The "ADAPT-232" Russian three-adaptogen combo (rhodiola + schisandra + eleuthero) does exist in clinical use, but the evidence for additivity over single-adaptogen use is thin.
• Schisandra: Russian "ADAPT-232" three-adaptogen combo; both mild stimulants
• Astragalus: Immune-modulation combo; common in Chinese herbal practice
• Echinacea + Adhatoda (KanJang fixed combination): Documented URTI synergy (Narimanian 2005, Materazzi 2015)
• Cordyceps / Reishi: Immune-modulation combos; mechanistic overlap, no head-to-head data
• Vitamin C (in V4 stack): General immune-support combo
• Panax ginseng: Compound adaptogen; increases stim-like signal — not recommended for stimulant-sensitive users

Avoid stacking with

• Other CNS stimulants at high doses (caffeine + modafinil + rhodiola + eleuthero simultaneously): Mild additive sympathomimetic; can cause anxiety + insomnia in stimulant-sensitive users
• Anticoagulants (warfarin): Theoretical interaction; case report of altered INR; mechanism unclear (possibly CYP1A2 or platelet effect); monitor if on warfarin
• Digoxin: Case report of falsely elevated serum digoxin (assay interference rather than pharmacological); monitor levels if on cardiac glycoside
• MAOIs (phenelzine): Theoretical pressor risk; not well-characterized

Neutral / safe co-administration

• Most V4 / V5 stack compounds — magnesium, zinc, omega-3, vitamin D, creatine, taurine, L-theanine, glycine, melatonin
• SSRIs / SNRIs: theoretical pharmacodynamic monitoring per dcInteractions block, but no clinical case-report literature supporting actual problems

Dylan stack-decision

• Do NOT stack with rhodiola simultaneously. Run as alternatives (rhodiola 6 weeks → eleuthero 6 weeks → rhodiola again, or simply stay on rhodiola which has better Western RCT support).
• Stack with vitamin C + zinc as a winter URTI-protection block during cold-and-flu season.

• Anticoagulants (warfarin): Case report of altered INR with eleuthero co-administration; theoretical platelet effect or CYP-mediated. Monitor.
• Digoxin: Case report of falsely elevated serum digoxin (assay interference rather than pharmacological); monitor by clinical effect if on cardiac glycoside.
• Diabetes medications (insulin, sulfonylureas, GLP-1 agonists): Mild hypoglycemic signal at high doses; monitor glucose if on antidiabetic therapy.
• Sedatives: Theoretical interaction in either direction; not well-characterized.
• CYP enzymes: Mild CYP3A4 induction reported (less than schisandra). CYP2B6 inhibition signal in recent literature — clinically relevant for bupropion (see dcInteractions block).
• MAOIs: Theoretical pressor risk via mild sympathomimetic action. Not well-characterized.
• Stimulants (amphetamine, methylphenidate, modafinil): Additive sympathomimetic signal at high doses; relevant in ADHD-stimulant context (monitor BP/HR if combining).
• No significant interaction expected with: SSRIs (theoretical CYP/HPA per dcInteractions, no clinical issue documented), NSAIDs, statins, antihypertensives at standard doses.

Not characterized. No actionable variants known.

• CYP3A4 (eleuthero is mildly inducing): poor metabolizers theoretically more sensitive to mild stimulating signal; no clinical data
• CYP2B6 (eleuthero may inhibit): relevant for bupropion clearance — see dcInteractions
• Glucocorticoid receptor (NR3C1) variants implicated in stress response — presumed relevance to adaptogen response but no direct studies on eleuthero

Practical takeaway: Genetics is not a useful filter for eleuthero decision-making at this point. Decide based on clinical phenotype (immune-frequency, asthenia, HSV outbreak history) rather than genotype.

Quality-control reality check: Patyra 2025 (PMID 41235111) found eleutheroside content varies 43-200× across commercial products, and 30-36% of market samples contained DNA-barcoding-identifiable adulterants. Branded standardized products from established vendors are dramatically more reliable than generic "Siberian ginseng" capsules — the latter can contain Panax, related Araliaceae species, or filler. For Dylan, NOW Foods or Nature's Way standardized capsule is the floor; below that quality tier the product is essentially unverified.

WADA / NCAA status: Eleuthero itself is not banned by WADA, USADA, NCAA, or MMA sanctioning bodies as of 2026. Sourcing risk is adulteration with banned compounds (rare in major-brand standardized products but real in fly-by-night Siberian-ginseng marketed supplements). For tested athletes — including Dylan in MMA-tested contexts — stick to NSF Certified for Sport / Informed Sport tested products.

Baseline (before starting eleuthero)

• AM cortisol (8:00 AM serum)
• hsCRP (inflammation baseline)
• CBC with differential (lymphocyte populations as proxy for immune baseline)
• Fatigue scale (FAS — Fatigue Assessment Scale, or Chalder Fatigue Scale)
• Sick days per quarter (subjective tracking — most useful for the URTI-protection use case)
• HSV outbreak frequency log (if HSV-2 indication)
• Blood pressure baseline (if at all hypertension-prone)

During use (4-8 weeks)

• Same panel at 8-12 weeks for trend
• Subjective energy / fatigue VAS daily for first 4 weeks (capture the onset window)
• Sick-day count vs same period prior year

Post-cycle

• Confirm sustained or rebound at 4-week off-cycle check
• If sick-day count or HSV outbreak frequency dropped meaningfully — consider next cycle

Outside Dylan's panel (not currently relevant)

• NK cell activity (research lab; not in standard clinical panels)
• Salivary cortisol AUC (research-grade chronic stress assessment; available through Dutch / Diagnos labs)